Vnitr̆ní lékar̆ství
-
Vnitr̆ní lékar̆ství · Jun 2015
[PEGASUS - Ticagrelor in secondary prevention on patients after a myocardial infarction].
Ticagrelor is a P2Y12 receptor antagonist that has been shown to reduce ischemic events for up to a year after an acute coronary syndrome. The efficacy and safety of long-term ticagrelor therapy beyond 1 year after a myocardial infarction is unknown. ⋯ Treatment of patients more than 1 year after a myocardial infarction with ticagrelor reduces the risk of cardi-ovascular death, myocardial infarction, or stroke, and increases the risk of major bleeding.Key words: myocardial infarction - secondary prevention - ticagrelor.